American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
EU Recovery Fund Faces Bottlenecks Despite Driving Digital and Green Projects 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand 
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Novartis, a global healthcare company, based in Basel, Switzerland, announced it would be undergoing a major restructuring, and in the process, thousands of jobs will be cut worldwide. The pharmaceutical company's reorganization has to be carried out as its combining its pharma and oncology business units.
As per Reuters, it was the Swiss newspaper Tages-Anzeiger that first published an article about Novartis' plans on Tuesday, April 12. The publication said that the details were shared by company sources that cannot be named.
While thousands of jobs worldwide will be affected by this move, over 100 roles may also vanish at Novartis' main site in Basel and Rotkreuz. Reuters reached out to the company for comments, and its spokesperson confirmed that the restructuring will "inevitably lead to roles being impacted." However, he said that it is still too early to determine the exact number of jobs that will disappear.
Currently, Novartis has 108,000 workers around the world, so this number will be reduced once the integration of its oncology and pharmaceutical units commences. The merger will create the company's innovative medicines (IM) business that will simplify its structure and save around $1 billion by 2024.
Novartis' spokesperson added that they are expecting the new structure to be completed and fully operational before this year ends. The simplified structure setup supports the firm's strategy as a focused medicines company, plus this was also planned to power its next phase of innovation, growth, and productivity.
"The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pipeline and drive value-creation through operational efficiencies," Novartis' chief executive officer, Vas Narasimhan, said in a press release.
He added, "With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid and long-term."
Finally, the revamp also resulted in changes to the company's Executive Committee of Novartis (ECN). Five executives were appointed to lead the firm in their new roles.
